Emerging fungal pathogens: Evolving challenges to immunocompromised patients for the twenty-first century

Transplant Infectious Disease

Volumn 1, Issue 4, 1999, Pages 247-261

  Walsh, T J ^a,b   Groll, A M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EPN 3108   (United States)

Author keywords

Fungal pathogens; Immunocompromised patients

Indexed keywords

AIDS RELATED COMPLEX; CLASSIFICATION; CROSS INFECTION; FUNGUS; HUMAN; IMMUNE DEFICIENCY; MICROBIOLOGY; MORTALITY; MYCOSIS; PATHOGENICITY; REVIEW;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CROSS INFECTION; FUNGI; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES;

EID: 0033302528     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.1999.010404.x     Document Type: Article

References (126)

1. WALTER EA, BOWDEN RA. Infection in the bone marrow transplant recipient. Infect Dis Clin North Am 1995: 9: 823-847.
2. HADLEY S, KARCHMER AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 1995: 9: 1045-1074.
3. FISHMAN JA, RUBIN RH. Infection in organ-transplant recipients. N Engl J Med 1998: 338: 1747-1751.
4. GROLL AH, SHAH PM, MENTZEL C, SCHNEIDER M, JUST-NUEBLING G, HUEBNER K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996: 33: 23-32.
5. ANAISSIE E. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review. Clin Infect Dis 1992:14 (Suppl 1): S43-53.
6. WINGARD JR. Importance of Candida species other than C albicans as pathogens in oncology patients. Clin Infect Dis 1995: 20: 115-125.
7. COLEMAN DC, RINALDI MG, HAYNES KA, et al. Importance of Candida species other than Candida albicans as opportunistic pathogens. Med Mycol 1998: 36 (Suppl 1): 156-165.
8. WALSH TJ, GONZALEZ C, ROILIDES E, et al. Fungemia in HIV-infected children: new epidemiologic patterns, emerging pathogens, and improved antifungal outcome. Clin Infect Dis 1995: 20: 900-906.
9. GIRMENIA C, MARTINO P, DE BERNARDIS F, et al. Rising incidence of C parapsilosis fungemia in patients with hematologic malignancies: Clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis 1996: 23: 506-514.
10. GONZALEZ CE, VENZON D, LEE S, MUELLER BU, PIZZO PA, WALSH TJ. Risk factors for fungemia in pediatric HTV-infection: a case control study. Clin Infect Dis 1996: 23: 515-521.
11. NGUYEN MH, PEACOCK JE JR, MORRIS A, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996: 100: 617-623.
12. REX JH, PFALLER MA, GALGIANI JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997: 24: 235-247.
13. NGUYEN MH, CLANCY CJ, YU VL, et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis 1998: 177: 425-430.
14. PANNUTI C, GINGRICH R, PFALLER MA, KAO C, WENZEL RP. Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors. Cancer 1992: 69: 2653-2662.
15. WALD A, LEISENRING W, VAN BURIK JA, BOWDEN RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997: 175: 1459-1466.
16. KANJ SS, WELTY-WOLF K, MADDEN J, et al. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine 1996: 75: 142-156.
17. TRITZ DM, WOODS GL. Fatal disseminated infection with Aspergillus terreus in immunocompromised hosts. Clin Infect Dis 1993: 16: 118-122.
18. FIELD RIDELY A, SUTTON D, PETRAITIS V, et al. Resistance of Aspergillus terreus to amphotericin B: in vitro/in vivo correlation of an emerging pathogen. Program and Abstracts of the 100th Annual Meeting of the Am Soc Microbiol (in press).
19. IWEN PC, RUPP ME, BISHOP MR, et al. Disseminated aspergillosis caused by Aspergillus ustus in a patient following allogeneic peripheral stem cell transplantation. J Clin Microbiol 1998: 36: 3713-3717.
20. ANAISSIE E, KANTARJIAN H, RO J, et al. The emerging role of Fusarium infections in patients with cancer. Medicine 1988: 67: 77-83.
21. Disseminated Fusarium infections in patients following bone marrow transplantation. Bone Marrow Transplant 1989: 4: 653-658.
22. NELSON PE, et al. Taxonomy, biology, and clinical aspects of Fusarium species. Clin Microbiol Rev 1994: 7: 479-504.
23. BOUTATI EI, ANAISSIE EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997: 90: 999-1008.
24. MARTINO P, GASTALDI R, RACCAH R, GIRMENIA C. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect Dis 1994: 28 (Suppl 1): 7-15.
25. MERZ W, KARP J, HOAGLAND M, et al. Diagnosis and successful treatment of fusariosis in the compromised host. J Infect Dis 1998: 158: 1046-1055.
26. WALSH TJ, FRANCESCONI A, KASAI M, CHANOCK S. Polymerase chain reaction and single strand conformational polymorphism (SSCP) for recognition of medically important opportunistic fungi. J Clin Microbiol 1995: 33: 3216-3220.
27. WALSH TJ, HIEMENZ JW, SEIBEL N, et al. Amphotericin B lipid complex in patients with invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998: 26: 1383-1396.
28. LOZANO-CHIU M, ARIKAN S, PAETZNICK VL, ANAISSIE EJ, LOEBENBERG D, REX JH. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother 1999: 43: 589-591.
29. MCGINNIS MR, PASARELL L, SUTTON DA, FOTHERGILL AW, COOPER Jr CR, RINALDI MG. In vitro activity of voriconazole against selected fungi. Med Mycol 1998: 36: 239-242.
30. SCHELL WA, PERFECT JR. Fatal, disseminated Acremonium strictum infection in a neutropenic host. J Clin Microbiol 1996: 34: 1333-1336.
31. ROILIDES E, BIBASHI E, ACRITIDOU E, et al. Acremonium fungemia in two immunocompromised children. Pediatr Infect Dis J 1995: 14: 548-550.
32. PERFECT JR, SCHELL WA. The new fungal opportunists are coming. Clin Infect Dis 1996: 22 (Suppl 2): S112-118.
33. ORTH B, FREI R, ITIN PH, et al. Outbreak of invasive mycoses caused by Paecilomyces lilacinus from a contaminated skin lotion. Ann Intern Med 1996: 125: 799-806.
34. SHING MM, IP M, LI CK, CHIK KW, YUEN PM. Paecilomyces variotii fungemia in a bone marrow transplant patient. Bone Marrow Transplant 1996: 17: 281-283.
35. CHAN-TACK KM, THIO CL, MILLER NS, KARP CL, HO C, MERZ WG. Paecilomyces lilacinus fungemia in an adult marrow transplant recipient. Med Mycol 1999: 37: 57-60.
36. NAIAD J, SINGH SM. Hyalohyphomycosis caused by Paeclomyces variotii: a case report, animal pathogenicity and 'in vitro' sensitivity. Antonie Van Leeuwenhoek 1992: 62: 225-230.
37. TAN TQ, OGDEN AK, TILLMAN J, DEMMLER GJ, RINAIDI MG. Paecilomyces lilacinus catheter-related fungemia in an immunocompromised pediatric patient. J Clin Microbiol 1992: 30: 2479-2483.
38. WILLIAMSON PR, KWON-CHUNG KJ, GALLIN JI. Successful treatment of Paecilomyces variotii infection in a patient with chronic granulomatous disease and a review of Paecilomyces species infections. Clin Infect Dis 1992: 14: 1023-1026.
39. LIU K, HOWELL DN, PERFECT JR, SCHELL WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Ammonium species by histopathology. Am J Clin Pathol 1998: 109: 45-54.
40. RICHTER S, et al. Fatal disseminated Trichoderma longibrachiatum infection in an adult bone marrow transplant patient: species identification and review of the literature. J Clin Microbiol 1999: 37: 1154-1160.
41. MUNOZ FM, et al. Trichoderma longibrachiatum infection in a pediatric patient with aplastic anemia. J Clin Microbiol 1997: 35: 499-503.
42. GAUTHERET A, et al. Trichoderma pseudokoningii as a cause of fatal infection in a bone marrow transplant recipient Clin Infect Dis 1995: 20: 1063-1064.
43. JACOBS F, et al. Trichoderma viride infection in a liver transplant recipient. Mycoses 1992: 35: 301-303.
44. KUHLS K, LIECKFELDT E, BÖRNER T, GUEHO E. Molecular identification of human pathogenic Trichoderma isolates of Trichoderma longibrachiatum and Trichoderma citroinviride. Med Mycol 1999: 37: 25-33.
45. KING D, CHEEVER LW, HOOD A, HORN TD, RINALDI MG, MERZ WG. Primary invasive cutaneous Microsporum canis infections in immunocompromised patients. J Clin Microbiol 1996: 34: 460-462.
46. GROSSMAN ME, et al. Invasive Trichophyton rubrum infection in the immunocompromised host: report of three cases. J Am Acad Dermatol 1995: 33: 315-318.
47. ENGELHARD D, et al. Treatment with itraconazole of widespread tinea corporis due to Trichophyton rubrum in a bone marrow transplant recipient Bone Marrow Transplant 1988: 3: 517-519.
48. ELEWSKI BE. Tinea capitis: itraconazole in Trichophyton tonsurans infection. J Am Acad Dermatol 1994: 1: 65-67.
49. VILLARS VV, JONES TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 1992: 126 (Suppl 39): 61-69.
50. GROLL A, WALSH TJ. Pharmacology of antifungal compounds. Adv Pharmacol 1998: 44: 343-500.
51. ARNOW PM, HOUCHLNS SG, PUGLIESE G. An outbreak of tinea corporis in hospital personnel caused by a patient with Trichophyton tonsurans infection. Pediatr Infect Dis J 1991: 10: 355-359.
52. MATSUMOTO T, AJELLO L, MATSUDA T, SZANISZLO PJ, WALSH TJ. Developments in phaeohyphomycosis and hyalohyphomycosis. J Med Vet Mycol 1994: 32 (Suppl 1): 329-349.
53. VUKMIR RB, KUSNE S, LINDEN P, et al. Successful therapy for cerebral phaeohyphomycosis due to Dactylaria gallopava in a liver transplant recipient. Clin Infect Dis 1994: 19: 714-719.
54. KRALOVIC SM, RHODES JC. Phaeohyphomycosis caused by Dactylaria (human dactylariosis): report of a case with review of the literature. J Infect 1995: 31: 107-113.
55. RINALDI MG. Phaeohyphomycosis. Dermatol Clin 1996: 14: 147-153.
56. FOTHERGILL AW. Identification of dematiaceous fungi and their role in human disease. Clin Infect Dis 1996: 22 (Suppl 2): S179-184.
57. JHA V, KRISHNA VS, CHAKRABARTI A, et al. Subcutaneous phaeohyphomycosis in a renal transplant recipient a case report and review of the literature. Am J Kidney Dis 1996: 28: 137-139.
58. PAUZNER R, GOLDSCHMIED-REOUVEN A, HAY I, et al. Phaeohyphomycosis following cardiac surgery: case report and review of serious infection due to Bipolaris and Exserohilurn species. Clin Infect Dis 1997: 25: 921-923.
59. DE HOOG GS. Significance of fungal evolution for the understanding of their pathogenicity, illustrated with agents of phaeohyphomycosis. Mycoses 1997: 40 (Suppl 2): 5-8.
60. SUTTON DA, SLIFKLN M, YAKULIS R, RINALDI MG. U.S. case report of cerebral phaeohyphomycosis caused by Ramichloridium obovoideum (R. mackenziei): criteria for identification, therapy, and review of other known dematiaceous neurotropic taxa. J Clin Microbiol 1998: 36: 708-715.
61. BERENGUER J, DIAZ-MEDIAVILLA J, URRA D, MUNOZ P. Central nervous system infection caused by Pseudallescheria boydii: Case report and review. Rev Infect Dis 1990: 11: 890-896.
62. PATTERSON TF, ANDRIOLE VT, ZERVOS MJ, THERASSE D, KAUFFMAN CA. The epidemiology of pseudallescheriasis complicating transplantation: nosocomial and community-acquired infection. Mycoses 1990: 33: 297-302.
63. GRIGG AP, PHILLIPS P, DURHAM S, SHEPHERD JD. Recurrent Psedallescheria boydii sinusitis in acute leukemia. Scand J Infect Dis 1993: 25: 263-267.
64. KERSHAW P, FREEMAN R, TEMPLETON D, et al. Pseudallescheria boydii infection of the central nervous system. Arch Neurol 1990: 47: 468-472.
65. TRAVIS LB, ROBERTS GD, WILSON WR. Clinical significance of Pseudallescheria boydii: A review of 10 years' experience. Mayo Clinic Proc 1985: 60: 531-537.
66. WELTY FK, MCLEOD GX, EZRATTY C, HEALY RW, KARCHMER AW. Pseudallescheria boydii endocarditis of the pulmonic valve in a liver transplant recipient. Clin Infect Dis 1992: 15: 858-560.
67. TADROS TS, WORKOWSKI KA, SIEGEL RJ, HUNTER S, SCHWARTZ DA. Pathology of hyalohyphomycosis caused by Scedosporium apiospermum (Pseudallescheria boydii): an emerging mycosis. Hum Pathol 1998: 29: 1266-1272.
68. WALSH TJ, PETER J, MCGOUGH DA, FOTHERGILL AW, RINALDI MG, PIZZO PA. Activity of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother 1995: 39: 1361-1364.
69. WOOD GM, MCCORMACK JG, MUIR DB, et al. Clinical features of human infection with Scedosporium inflatum. Clin Infect Dis 1992: 14: 1027-1033.
70. LOPEZ FA, CROWLEY RS, WASTILA L, VALANTINE HA, REMLNGTON JS. Scedosporium apiospermum (Pseudallescheria boydii) infection in a heart transplant recipient: a case of mistaken identity. J Heart Lung Transplant 1998: 17: 321-324.
71. PHILLIPS P, FORBES JC, SPEERT DP. Disseminated infection with Pseudallescheria boydii in a patient with chronic granulomatous disease: response to gamma-interferon plus antifungal chemotherapy. Pediatr Infect Dis J 1991: 10: 536-539.
72. ROILIDES E, UHLIG K, VENZON D, PIZZO PA, WALSH TJ. Enhancement of oxidative response and damage caused by neutrophils to Aspergillus fumigatus hyphae by granulocyte colony stimulating factor and interferon-gamma. Infection and Immunity 1993: 61: 1185-1193.
73. SHARKEY K, GRAYBILL JR, RINALDI MG, et al. Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol 1990: 23: 577-586.
74. ANTOINE GA, RATERNIK MH. Bipolaris: a serious new fungal pathogen of the paranasal sinus. Otolaryngol Head Neck Surg 1989: 100: 158-162.
75. ADAM RD, PAQUIN ML, PETERSEN EA, SAUBELLE MA, RINALDI MG. Phaeohyphomycosis caused by the fungal genera Bipolaris and Exserohilum. A report of nine cases and review of the literature. Medicine 1986: 65: 203-217.
76. JACOBSON M, GALETTA SL, ATLAS SW, CURTIS MT, WULC AW. Bipolaris-induced. orbital cellulitis. J Clin Neuroophthalmol 1992: 12: 250-256.
77. MASKIN SL, FETCHICK RJ, LEONE CR JR, SHARKEY PK, RINALDI MG. Bipolaris hawaiiensis-caused phaeomycotic orbitopathy. A devastating fungal sinusitis in an apparently immunocompetent host. Ophthalmology 1989: 96: 175-179.
78. MORTON SJ, MIDTHUN K, MERZ WG. Granulomatous encephalitis caused by Bipolaris hawaiiensis. Arch Pathol Lab Med 1986: 110: 1183-1185.
79. FLANAGAN KL, BRYCESON AD. Disseminated infection due to Bipolaris australiensis in a young immunocompetent man: case report and review. Clin Infect Dis 1997: 25: 311-313.
80. DIXON DM, WALSH TJ, MERZ WG, MCGINNIS MR. Human central nervous system infections due to Xylohypha bantiana (Cladosporium trichoides). Rev Infect Dis 1989: 11: 515-525.
81. GOEL A, SATOSKAR A, DESAI AP, PANDYA SK. Brain abscess caused by Cladosporium trichoides. Br J Neurosurg 1992: 6: 591-593.
82. ALDAPE KD, FOX HS, ROBERTS JP, ASCHER NL, et al. Gadosporium trichoides cerebral phaeohyphomycosis in a liver transplant recipient. Report of a case. Am J Clin Pathol 1991: 95: 499-502.
83. EMMENS RK, RICHARDSON D, THOMAS W, et al. Necrotizing cerebritis in an allogeneic bone marrow transplant recipient due to Cladophialophora bantiana. J Clin Microbiol 1996: 34: 1330-1332.
84. SUGAR AM. Mucormycosis. Clin Infect Dis 1992: 14 (Suppl 1): S126-129.
85. IRWIN RG, RINALDI MG, WALSH TJ. Zygomycosis of the respiratory tract. In: SAROSI G, DAVIES S, eds. Fungal Diseases of the Lung, (3rd edn) Philadelphia: Lippincott Williams & Wilkins, 1999: (in press).
86. FINGEROTH JD, ROTH RS, TALCOTT JA, RINALDI M. Zygomycosis due to Mucor circinelloides in a neutropenic patient receiving chemotherapy for acute myelogenous leukemia. Clin Infect Dis 1994: 19: 135-137.
87. AL-HAIJAR S, PERFECT J, HASHEM F, TUFENKEJI H, KAYES S. Orbitofascial conidiobolomycosis in a child. Pediatr Infect Dis J 1996: 15: 1130-1132.
88. WALSH TJ, RENSHAW G, ANDREWS J, et al. Invasive zygomycosis due to Conidiobolus incongnius. Clin Infect Dis 1994: 19: 423-430.
89. KONTOYIANIS DP, VARTIVARIAN S, ANAISSIE EJ, et al. Infections due to Cunninghamella bertholletiae in patients with cancer: report of three cases and review. Clin Infect Dis 1994: 18: 925-928.
90. KOLBECK PC, MAKHOUL RG, BOLLINGER RR, et al. Widely disseminated Cunninghamella mucormycosis in an adult renal transplant patient: Case report and review of the literature. Am J Clin Pathol 1985: 83: 747.
91. REX JH, GINSBERG AM, FRIES LF, PASS HI, KWON-CHUNG KJ. Cunninghamella bertholletiae infection associated with deferoxamine therapy. Rev Infect Dis 1988: 10: 1187-1194.
92. NIMMO GR, WHITING RF, STRONG RW. Disseminated mucormycosis due to Cunninghamella bertholleiae in a liver transplant recipient. Postgrad Med J 1988: 64: 82-84.
93. COOTER RD, LIM IS, ELLIS DH, LEITCH IO. Burn wound zygomycosis caused by Apophysomyces elegans. J Clin Microbiol 1990: 28: 2151-2153.
94. ROBERTSON AF, JOSHI W, ELLISON DA, CEDARS JC. Zygomycosis in neonates. Pediatr Infect Dis J 1997: 16: 812-815.
95. GONZALEZ CE, COURIEL DR, WALSH TJ. Successful treatment of disseminated zygomycosis in a neutropenic patient with amphotericin B lipid complex and granulocyte colony stimulating factor. Clin Infect Dis 1997: 24: 192-196.
96. PERFECT J, CASADEVAL A. Cryptococcus neoformans. ASM Press, 1998.
97. KORFEL A, MENSSEN HD, SCHWARTZ S, THIEL E. Cryptococcosis in Hodgkin's disease: description of two cases and review of the literature. Ann Hematol 1998: 76: 283-286.
98. ABERG JA, POWDERLY WG. Cryptococcosis. Adv Pharmacol 1997: 37: 215-251.
99. WHITE MH, ARMSTRONG D. Cryptococcosis. Infect Dis Clin North Am 1994: 8: 383-398.
100. DISMUKES WE. Management of cryptococcosis. Clin Infect Dis 1993: 17 (Suppl 2): S507-512.
101. PAPPAS PG, PERFECT J, LARSEN RA, et al. Cryptococcosis in HIV-negative patients: analysis of 306 cases. Abstracts (No.101) of the Infect Dis Soc Am 36th Annual Meeting p. 94.
102. WALSH TJ, NEWMAN KR, MOODY M, WHARTON RC, WADE JC. Trichosporonosis in patients with neoplastic disease. Medicine 1986: 65: 268-279.
103. HOY J, HSU K, ROLSTON K, HOPFER RL, LUNA M, BODEY GP. Trichosporon beigelii infection: A review. Rev Infect Dis 1986: 8: 959-967.
104. WALSH TJ, MELCHER G, RINALDI M, et al. Trichosporon beigelii: an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990: 28: 1616-1622.
105. WALSH TJ, MELCHER GP, LEE JW, PIZZO PA. Infections due to Trichosporon species: new concepts in mycology, pathogenesis, diagnosis, and treatment. Curr Top Med Mycol 1993: 5: 79-113.
106. LEE JW, MELCHER GA, RINALDI MG, ANDREWS J, PIZZO PA, WALSH TJ. Patterns of morphologic variation in strains of Trichosporon beigelii. J Clin Microbiol 1990: 28: 2823-2827.
107. KEMEKER BJ, LEHMAN PF, LEE JW, WALSH TJ. Distinction of deep vs. superficial clinical and non-clinical environmental isolates of Trichosporon beigelii by isoenzymes and RFLPs of rDNA generated by the polymerase chain reaction. Antimicrob Agents Chemother 1991: 29: 1677-1683.
108. GUEHO E, SMITH MT, dE HOOG GS, et al. Contributions to a revision of the genus Trichosporon. Antonie Van Leeuwenhoek 1992: 61: 289-316.
109. MCMANUS EJ, JONES JM. Detection of a Trichosporon beigeiii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol 1985: 21: 681.
110. MELCHER GA, REED KD, RINAIDI MG, LEE JW, PIZZO PA, WAISH TJ. Demonstration of a cell wall antigen cross-reacting with cryptococcal polysaccharide in experimental disseminated trichosporonosis. J Clin Microbiol 1991: 29: 192-196.
111. LYMAN CA, DEVI S, NATHANSON J, FRASCH CE, PIZZO PA, WALSH TJ. Detection and quantification of the glucuronoxylomannan-like polysaccharide antigen from clinical and non-clinical isolates of Trichosporon beigelii: implications for pathogenecity. J Clin Microbiol 1994: 33: 126-130.
112. LYMAN CA, GARRET KF, PIZZO PA, WALSH TJ. Response of human polymorphonuclear leukocytes and monocytes to Trichosporon beigelii: host defense against an emerging pathogen. J Infect Dis 1994: 170: 1557-1565.
113. WAISH TJ, LEE JW, MELCHER GP, et al. Experimental disseminated trichosporonosis in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic infection. J Infect Dis 1992: 166: 121-133.
114. ANAISSIE E, GOKOSLAN A, HACHEM R, RUBIN R. Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis 1992: 15: 781-787.
115. MELEZ KA, CHERKY J, SANCHEZ C, ETTINGER RB, WALSH TJ. Successful outpatient treatment of Trichosporon beigelii peritonitis with oral fluconazole. Pediatr Infect Dis J 1995: 14: 1110-1113.
116. CHARIYALERTSAK S, SIRISANTHANA T, SUPPARATPINO K, NELSON KE. Seasonal variation of disseminated Penicillium marneffei infections in northern Thailand: a clue to the reservoir? J Infect Dis 1996: 173: 1490-1493.
117. SIRISANTHANA V, SIRISANTHANA T. Disseminated Penicillium marneffei infection in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1995: 14: 935-940.
118. SUPPARATPINYO K, NELSON KE, MERZ WG, et al. Response to antifungal therapy by human immunodeficiency virus infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother 1993: 37: 2407-2411.
119. SUPPARATPINYO K, KHAMWAN C, BAOSOUNG V, NELSON KE, SIRISANTHANA T. Disseminated Penicillium marneffei infection in Southeast Asia. Lancet 1994: 344: 110-113.
120. VANITTANAKOM N, COOPER CR JR, CHARIYALERTSAK S, YOUNGHIM S, NELSON KE, SIRISANTHANA T. Restriction endonuclease analysis of Penicillium marneffei. J Clin Microbiol 1996: 34: 1834-1836.
121. SUPPARATPINYO K, PERRIENS J, NELSON KE, SIRISANTHANA T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med 1998: 339: 1739-1743.
122. SIRISANTHANA T, SUPPARATPINYO K, PERRIENS J, NELSON KE. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis 1998: 26: 1107-1110.
123. GALGIANI JN. Coccidioidomycosis: a regional disease of national importance. Rethinking approaches for control. Ann Intern Med 1999: 130: 293-300.
124. PAPPAGIANIS D. Marked increase in cases of coccidioidomycosis in California: 1991, 1992, and 1993. Clin Infect Dis 1994: 19 (Suppl 1): S14-18.
125. GEORGOPAPADAKOU N, WALSH TJ. Antifungal therapy: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother 1996: 40: 279-291.
126. GROLL AH, DE LUCCA AJ, WALSH TJ. Emerging targets for novel antifungal therapeutics. Trends Microbiol 1998: 6: 117-124.